Metropolis Healthcare Ltd. · NSE:METROPOLIS
Metropolis Healthcare — Q2 & H1 FY26 Earnings Presentation
31 slides from Metropolis Healthcare's earnings presentation, Nov 4, 2025
Slide 1: Investor Presentation filing cover letter
Ref: MHL/Sec&Legal/2025-26/70 November 04, 2025 To, BSE Limited National Stock Exchange of India Ltd. Scrip Code: 542650 Scrip Symbol: METROPOLIS Dear Sir/Madam, Sub: Investor Presentation Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we a
Slide 2: Metropolis Healthcare Limited Q2 & H1FY26 Investor Presentation
METROPOLIS HEALTHCARE LIMITED Q2 & H1FY26 INVESTOR PRESENTATION
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Metropolis Healthcare Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any
Slide 4: Metropolis – Diagnostics that's trusted by doctors and patients alike
Metropolis – Diagnostics that’s trusted by doctors and patients alike OUR VISION To be a respected healthcare brand trusted by 43+ years of clinicians, patients and stakeholders. 11% CAGR credible Positively impact the lives of patients in their revenue growth experience most anxious times and turn
Slide 5: Performance & Company Updates – Q2FY26
Performance & Company Updates – Q2FY26 Important Updates & Definitions: 1. MHL Group – Includes acquisitions of Core Diagnostics, DAPIC - Dehradun and Scientific Pathology - Agra MHL Group MHL Organic 01 Key Financials (Page 4) 07 Speciality Business (Page 12) 2. MHL Organic – Excludes recent acquis
Slide 6: Q2 & H1FY26 Key Financials – MHL Group
Q2 & H1FY26 Key Financials – MHL Group Q2FY26 • Revenue growth fueled by organic Revenue EBITDA PAT business & acquisitions • Q2FY26, EBITDA margin at group level INR 429 Cr INR 109 Cr INR 53 Cr stood at 25.4% compared to 23.1% in +23% YoY +19% YoY +13% YoY Q1FY26 • Core Diagnostics EBITDA Margins i
Slide 7: Q2 & H1FY26 Key Financials – MHL Organic
Q2 & H1FY26 Key Financials – MHL Organic Q2FY26 • Organic business grew in double digits Revenue EBITDA PAT consistently • Growth was driven by robust INR 392 Cr INR 105 Cr INR 53 Cr momentum in preventive health check - +12% YoY +15% YoY +14% YoY ups like TruHealth and other specialty segments insp
Slide 8: Q2FY26 Key Performance Indicators MHL Organic Business
Q2FY26 Key Performance Indicators MHL Organic Business Excludes recent acquisitions of Core Diagnostics, DAPIC - Dehradun and Scientific Pathology - Agra 6
Slide 9: Q2FY26 Key Performance Indicators
Q2FY26 Key Performance Indicators B2C Revenue B2B Revenue • Despite lower seasonal illness incidence, Patient Volume performance remained strong, reflecting portfolio strength and growing demand 3.6 Mn INR 230 Cr INR 162 Cr for preventive health. +6% YoY +11% YoY +14% YoY • B2B segment consistently
Slide 10: Consistently Delivering Patient & Test Volume Growth
Consistently Delivering Patient & Test Volume Growth Patient Volume (in Mn) Test Volume (in Mn) Q2FY26 Segment Contribution Q2FY26 Segment Revenue Growth 9.7% Routine 4% 6% 6% 6% Routine 18% 17% Semi-Special 8% 7.44 Semi-Special 3.37 3.56 7.03 Specialty 27% Specialty 15% 38% TruHealth TruHealth 21%
Slide 11: B2C revenue growth @ 11% YoY
B2C revenue growth @ 11% YoY • B2C patient volume grew 5%, with a 6% increase in revenue per patient, driven by high-value scientific upselling • B2C TruHealth and Specialty segments led growth, powered by 59% new test additions and our Next +20% Best Action engine • B2C volumes softened due to lowe
Slide 12: B2B revenue growing by 14% YoY
B2B revenue growing by 14% YoY • B2B patient volumes grew 6%, with a 8% rise in RPP, supported by hospital-led high-value outsourcing • Clinical trial business, delivered 41% strong contribution, aligning with +30% our specialty focus – one time contract +14% +15% • Micro-market relevant Bundle pack
Slide 13: TruHealth Revenue grew @ 21% YoY for Q2FY26
TruHealth Revenue grew @ 21% YoY for Q2FY26 o Strong Revenue Momentum, Premium Mix & Digital Acceleration • Premium TruHealth packages (higher RPP) with home-based ECG, vital checks, and Growth consultations now form 22% of the TruHealth portfolio, reinforcing preventive leadership. • Radiology-inte
Slide 14: Speciality Revenue grew @ 15% YoY for Q2FY26
Speciality Revenue grew @ 15% YoY for Q2FY26 o Accelerating Specialty Leadership through Science, AI, and Clinician Trust Specialty • AI-based allergy testing grew 3X YoY, the fastest in the market, reinforcing Metropolis’ Growth leadership in precision-driven, AI-enabled diagnostics with superior a
Slide 15: Q2FY26 Key Performance Indicators MHL Group
Q2FY26 Key Performance Indicators MHL Group Includes recent acquisitions of Core Diagnostics, DAPIC - Dehradun and Scientific Pathology – Agra 13
Slide 16: Q2FY26 Key Performance Indicators
Q2FY26 Key Performance Indicators Q2FY26 Segment Contribution Patient Volume B2C Revenue B2B Revenue 17% 17% Routine Semi-Special 3.7 Mn INR 240 Cr INR 189 Cr Specialty 26% +11% YoY +16% YoY +33% YoY TruHealth 40% Q2FY26 Segment Revenue Growth Test Volume RPT RPP Routine 14% Semi-Special 14% 7.9 Mn
Slide 17: Diversified Revenue contribution across Geographies
Diversified Revenue contribution across Geographies Contribution from North India has increased to 19% Revenue Contribution Revenue Contribution (MHL Categorisation) By Region South 30% 27% East 50% Q2FY25 Q2FY26 55% 4% North 4% West 11% 19% (MHL Categorisation) Revenue Contribution Revenue Contribu
Slide 18: Network Expansion – Robust expansion with consolidation laying strong base
Network Expansion – Robust expansion with consolidation laying strong base Laboratory Network Service Network 210 221 199 4,150 4,536 4,750 175 3,675 904 161 870 805 +2,195 119 124 125 +96 2,731 2,555 3,134 754 2,336 704 Centres Labs 575 598 498 3,135 3,236 2,914 2,594 2,105 Rural 1,873 1,806 1,506
Slide 19: Q2FY26 Profit & Loss Statement
Q2FY26 Profit & Loss Statement Q2FY26 (MHL Q2FY26 (MHL Profit & Loss Statement (Rs. Crs.) Q2FY25 Organic) Y-o-Y Y-o-Y Group) Revenue from Operations 349.8 391.7 12.0% 429.2 22.7% Total Cost 258.3 286.9 320.3 Reported EBITDA 91.5 104.8 14.6% 108.9 19.1% Reported EBITDA (%) 26.2% 26.8% 25.4% Depreciat
Slide 20: H1FY26 Profit & Loss Statement
H1FY26 Profit & Loss Statement H1FY26 (MHL H1FY26 (MHL Profit & Loss Statement (Rs. Crs.) H1FY25 Y-o-Y Y-o-Y Organic) Group) Revenue from Operations 663.1 746.4 12.6% 815.3 22.9% Total Cost 493.5 554.1 617.3 Reported EBITDA 169.7 192.3 13.3% 198.0 16.7% Reported EBITDA (%) 25.6% 25.8% 24.3% Deprecia
Slide 21: Consolidated Balance Sheet
Consolidated Balance Sheet Assets (Rs. Crs.) Sep-25 Mar-25 Equity & Liabilities (Rs. Crs.) Sep-25 Mar-25 Non-current assets 1,641.9 1,521.4 Equity 1,443.1 1,334.6 Property, Plant and Equipment 202.8 190.3 Equity Share capital 10.4 10.4 ROU Assets 160.8 170.3 Other equity 1,422.1 1,320.6 Goodwill 664
Slide 22: Metropolis 3.0
Metropolis 3.0 METROP®OLIS
Slide 23: Key Pillars of Metropolis 3.0 Strategy – poised to grow further
Key Pillars of Metropolis 3.0 Strategy – poised to grow further 1 Strengthening the Core Expand market share in core and new geographies with focus on specialized and wellness testing, strengthening Top 800 towns via Micro Market Strategy, T3 Acceleration, and breakthrough asset Expand to Adjacencie
Slide 24: Driving business growth through Digital Transformation
Driving business growth through Digital Transformation Metropolis is a unique Healthcare Company equipped with CDP, Marketing Cloud, Service Cloud, Sales Cloud, Community Cloud Accurate Efficient 360-Degree Opportunity Case Relationship Reporting & Cross Channel Enhanced Efficient Patient Billing &
Slide 25: Scientifically driven with strong focus on quality, research and academics
Scientifically driven with strong focus on quality, research and academics Scientific Expansion in Test Menu • New test launched across Oncology, Nephrology, Gynecology and 57+ New Tests added in H1FY26 Infectious and Chronic disease segment • Focus on NGS/molecular genomics segment growing driven b
Slide 26: Metropolis ESG Goals
Metropolis ESG’ Goals • Carbon Neutrality by 2043 Emission Goals for a Greener Tomorrow • 45% reduction in emissions intensity by 2030 Well identified ESG Focus Areas and assessments created e as per the materiality matrix based on the GRI, SASB and SDG Frameworks. • Zero waste in offices by 2030 Ac
Slide 27: Key ESG Plans
Key ESG Plans Emissions & Water & Waste Employee Risk Management Patient Privacy and Energy Management Recruitment, Electronic Health Development and Records • Achieve 5% reduction in Retention • Achieve 10% reduction in water usage through energy consumption through • Career 2.0 Campaign to increas
Slide 28: CSR at Metropolis – creating a positive impact
CSR at Metropolis – creating a positive impact Preventive Healthcare MedEngage Too Shy to Ask Projects (TSTA) • 365 scholarships, including 43 research grants, • TSTA Rural focused on adolescent reproductive • 1,000 TB patients received nutritional support in were awarded under the MedEngage Program
Slide 29: 'Promoter led – Professionally driven' organisation
‘Promoter led – Professionally driven’ organisation Dr. Sushil Shah Ameera Shah Surendran Chemmenkotil Founder & Non – Executive Promoter & Executive Chairperson Managing Director Non - Independent Director Dynamic Leadership Team for Next Level of Growth Dr. Nilesh Shah Sameer Patel Diya Suri Dr. K
Slide 30: Recent Awards and Accolades
Recent Awards and Accolades Dr Sushil Shah and Ameera Shah felicitated with the Hurun India’s Family Business Sept’25 Excellence Award for the year 2025. Sept’25 Ameera Shah - Influential Leader of India Award 2025 by Marksmen Daily Metropolis Healthcare – Most Innovative Organizations Award by ET N
Slide 31: For further information, please contact
For further information, please contact: Company : Investor Relations Advisors : http://www.sgapl.net/images/sgapl_logo.jpg Metropolis Healthcare Ltd. Strategic Growth Advisors Pvt. Ltd. CIN – L73100MH2000PLC192798 CIN - U74140MH2010PTC204285 Mr. Kamlesh Kulkarni Mr. Shogun Jain / Mr. Sagar Shroff E
Metropolis Healthcare — Q2 & H1 FY26 Earnings Presentation on 6ix